Investor Relations

Corporate ProfileNuvectra® is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $16.270.00 (0.00%)
ExchangeNASDAQ
Volume0
Today's Open$0.00
Previous Close$16.27
Data as of 12/17/18 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $16.27 with a 52 week high of $25.17 and a 52 week low of $7.60.

Recent News

December 12, 2018

Nuvectra Receives Full-Body MR-Conditional CE Mark Approval for Algovita®

PLANO, Texas, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has received full-body MR-conditional approval for the Company’s Algovita SCS system from its European Notified Body, TÜV SÜD. The approval closely follows the Company’s announcement regarding its receipt of head-only MR-conditional approval for Algovita from the U.S. Food and Drug Administration (FDA). Scott Drees, Chief Executive Officer,

Read More >

December 06, 2018

Nuvectra Completes 3,000 U.S. Algovita® SCS Implantations

PLANO, Texas, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that the Company’s Algovita® Spinal Cord Stimulation (SCS) system has been implanted in over 3,000 patients in the U.S. The Algovita system utilizes patent-protected stretchable lead technology with a robust internal pulse generator to deliver four stimulation modes to patients for non-pharmaceutical relief of pain. Scott Drees, Chief Executive Offi

Read More >


Investor Contact

The Ruth Group
Brian Johnston
Tram Bui
investors@nuvectramed.com

Events
There are currently no events scheduled.